- Home
- RSLS vs ATXI Comparison
RSLS vs ATXI Comparison
Compare RSLS & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- ATXI
- Stock Information
- Founded
- RSLS 2002
- ATXI 2015
- Country
- RSLS United States
- ATXI United States
- Employees
- RSLS N/A
- ATXI N/A
- Industry
- RSLS Medical/Dental Instruments
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- ATXI Health Care
- Exchange
- RSLS Nasdaq
- ATXI Nasdaq
- Market Cap
- RSLS 3.1M
- ATXI 3.0M
- IPO Year
- RSLS 2007
- ATXI 2017
- Fundamental
- Price
- RSLS $4.38
- ATXI $1.77
- Analyst Decision
- RSLS Hold
- ATXI
- Analyst Count
- RSLS 1
- ATXI 0
- Target Price
- RSLS N/A
- ATXI N/A
- AVG Volume (30 Days)
- RSLS 30.3K
- ATXI 28.0K
- Earning Date
- RSLS 11-14-2024
- ATXI 11-14-2024
- Dividend Yield
- RSLS N/A
- ATXI N/A
- EPS Growth
- RSLS N/A
- ATXI N/A
- EPS
- RSLS N/A
- ATXI N/A
- Revenue
- RSLS $8,183,000.00
- ATXI N/A
- Revenue This Year
- RSLS $17.47
- ATXI N/A
- Revenue Next Year
- RSLS $20.00
- ATXI N/A
- P/E Ratio
- RSLS N/A
- ATXI N/A
- Revenue Growth
- RSLS N/A
- ATXI N/A
- 52 Week Low
- RSLS $4.09
- ATXI $1.60
- 52 Week High
- RSLS $29.00
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- RSLS 32.94
- ATXI 41.33
- Support Level
- RSLS $4.09
- ATXI $1.63
- Resistance Level
- RSLS $4.80
- ATXI $1.92
- Average True Range (ATR)
- RSLS 0.40
- ATXI 0.13
- MACD
- RSLS -0.06
- ATXI -0.00
- Stochastic Oscillator
- RSLS 18.24
- ATXI 42.42
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.